Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors in the central anxious method, conolidine modulates alternate molecular targets. A Science Innovations research found that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://victorg284aqg9.wikicorrespondent.com/user